Cannabis Therapy Corp. Appoints Science Pioneer Dr. Cohava Gelber to Board

Cannabis Therapy Corp. Appoints Science Pioneer Dr. Cohava Gelber to Board 
Company Appointment Demonstrates Commitment to Scientific Excellence 
NEW YORK, NY -- (Marketwired) -- 04/15/14 --  Cannabis Therapy Corp.
(OTCQB: CTCO) (the "Company") a development stage enterprise focused
on the business of manufacturing and marketing pharmaceutical level
products containing phytocannabinoids, an abundant and
pharmaceutically active component of cannabis, for the treatment of
various conditions and diseases, is very pleased to confirm the
expert services of Dr. Cohava Gelber through her appointment to its
growing Board of Directors. 
Cohava Gelber, PhD, MBA, is an executive with over 25 years of
experience in discovery and development of immune therapeutics and
diagnostics for cancer, autoimmune disease, allergies and infectious
diseases. Dr. Gelber held various executive positions in academia
(Duke University) and biopharmaceutical companies (ImmuLogic
Pharmaceutical Corporation, Molecular Discoveries and MannKind
Corporation). Throughout her accomplished career, Dr. Gelber has
pioneered and built various science companies, departments and
proprietary platform technologies. 
Dr. Gelber has recently launched Caerus Discovery, LLC (CDL) with
support from Biowa/ Kyowa Hakko Kirin and ImmunoCellular
Therapeutics, Inc. CDL 's mission is to discover and develop new
antibody-based therapeutics. Prior to founding CDL, Dr. Gelber served
as the Chief Scientific & Technology Officer of ATCC (2005-2010), VP
of R&D for MannKind Corp -- a public company developing therapeutics
for diabetes, cancer and autoimmune diseases (2001-2005). She was
responsible for non-clinical development and clinical immune safety
of drugs from pre IND through phase III clinical trials. Dr. Gelber
published numerous scientific manuscripts and textbook chapters and
she is the inventor of 11 granted patents and 57 patent applications.
Dr. Gelber is board member of Etubics, Serpin Pharma and Caerus
Discovery and on the Scientific Advisory Board of George Mason
University, Libraries, NeuroQuest, MicroVax and Immuno Cellular
Therapeutics. Dr. Gelber received her Ph.D. from the Weizmann
Institute, her MBA degree from Cornell University and post doctorate
training at Stanford University. 
Cannabis
 Therapy Corp President & CEO Soren Mogelsvang comments, "We
are delighted to inform the public of this important appointment
today. The proven scientific input and extraordinary visionary
capabilities Dr. Gelber brings to our Company signals a clear message
of our intent to create a high quality science-based enterprise
focused on value generation in this rapidly growing sector. I thank
our newest Director for joining with us at this timely juncture as we
move ahead quickly to achieve our aims." 
Additional details of the Company's business, finances, appointments
and agreements can be found as part of the Company's continuous
public disclosure as a reporting issuer with the Securities and
Exchange Commission ("SEC") available at www.sec.gov. For more
information please visit www.cannabistherapy.com.  
About Cannabis Therapy Corp. (OTCQB: CTCO)
 Cannabis Therapy Corp.
aims to develop and market safe, phytocannabinoid-based medicinal
products and to apply rigorous manufacturing and quality control
standards to become a global leader in the research, development,
manufacturing, testing and marketing of cannabinoid ingredients and
therapies. For more information visit www.cannabistherapy.com. 
Safe Harbor Statement 
 Any statements contained in this press
release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors that
could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties
relating to the availability of additional funding; and the Company's
business, product development, marketing and distribution plans and
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including, the
Company's current reports on Form 8-K. The Company does not undertake
to update these forward-looking statements. 
ON BEHALF OF THE BOARD, 
Soren Mogelsvang, President & CEO
 Cannabis Therapy Corp.  
For additional information, please contact:
Cannabis Therapy Corp. Investor Relations
E: investors@cannabistherapy.com
T: +1 (800) 713-9091 
 
 
Press spacebar to pause and continue. Press esc to stop.